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INTRODUCTION 
 
Nucleolus and ribosome biogenesis 
 
The nucleolus is the most distinctive nuclear sub-compartment and is the site of the 
ribosome biogenesis. The nucleolus contains hundreds of ribosomal genes that are 
tandemly repeated in several chromosomes and which account for one-half of the total 
cellular RNA production. These chromosomal gene clusters  identified in mitotic 
chromosomes are known as NORs (nucleolar organizer regions). NORs were first 
described by Heitz and by McClintock in plant cells, as chromatinic regions around 
which nucleoli reform during telophase. These regions correspond to secondary 
constrictions of metaphase chromosome of eukaryotic cells (Howell 1982). In man 
secondary constrictions are localized on short arms of chromosomes 13, 14, 15, 21 and 
22. NORs are characterized by the presence of proteins that are selectively stained by 
silver methods (Howell 1982). During interphase, the nucleolus is the only site where 
both ribosomal genes and silver-stained proteins are located. The fibrillar components 
of the nucleolus are the interphase counterpart of the metaphase NORs. Interphase 
NORs have become an object of attention for pathologists because their distribution in 
the nucleolus has been shown to constitute a useful tool for differentiating, at the optical 
level, malignant from benign lesions in histological and cytological routine 
preparations. Abnormalities of the nucleolar morphology characterize neoplastic cells: 
hypertrophied and irregularly shaped nucleoli are frequently observed in cancer cells 
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(Koller 1963). A higher quantity of interphase NORs is generally observed in neoplastic 
cells than in the corresponding non-neoplastic cells (Derenzini 1991). 
 
 
Figure 1 Silver staining for the AgNOR proteins. A, A large amount of AgNOR proteins is 
present within nucleoli of the rapidly proliferating tumor mass, while B, only a few silver 
stained dots are present within cancer cells of the slowly proliferating mass.  
 
Only a subpopulation of rRNA genes is active at any given time. Indeed ribosomal 
RNA genes exists in two different types of chromatin, an open conformation that allow 
transcription and a closed conformation that is transcriptionally inactive. DNA 
methylation and histone modifications are the epigenetic mechanism responsible for the 
alterations in the chromatin structure resulting in the activation or silencing of rRNA 
genes (Grummt 2003). 
The biogenesis of ribosomes requires the initial transcription of rDNA genes by a 
specialized RNA Polymerase, RNA Polymerase I. It requires auxiliary factors that 
mediate promoter recognition, promote transcription elongation, and facilitate 
transcription termination. Together with the Polimerase I, upstream binding factor 
(UBF) and the promoter selectivity factor (SL1) are recruited in the promoter region 
enabling the formation of an active transcription complex. This pre-initiation complex 
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synthesizes the 47S precursor rRNA that contains in addition to the 18S, 5.8S and 28S 
rRNA sequences, internal and external transcribed spacer sequences (Moss et al. 2007).  
                                     
Figure 2 Electron microscopy of a nucleolus from human cells. The granular (g) and dense 
fibrillar (f ) components as well as the fibrillar centers (FC) are shown.  
 
Production of ribosome is largely controlled at the level of rRNA transcription: in 
addition to the epigenethic mentioned above, alterations in the extent of rDNA 
transcription can also occur via changes to the rate of transcription from each active 
rRNA gene. In mammalian cells rDNA transcription is a cell-cycle regulated process. 
Cell cycle control elements, like cdk-cyclin complexes and various oncogenes and 
oncosuppressors, regulate the production of rRNA. Moreover transcription rate varies 
during different phases of the cell cycle: it’s absent during mitosis, when the 
concomitant disappearance of the nucleolus is observed, gradually increases during G1 
and peaks in the S and G2 phases (Russell et al. 2005; Weisenberger et al. 1995). 
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The biogenesis of mature ribosomal RNA is a complex process (Fatica and Tollervey 
2002; Tschochner and Hurt 2003) that necessitates non-ribosomal proteins and 
ribonucleoproteins (RNPs) containing large varieties of small nucleolar RNAs 
(snoRNAs): endonucleases and exonucleases remove the non-coding transcribed spacer 
sequences before the assembly of the small and large ribosomal subunits in nucleolus; 
pseudouridine synthases and methyltransferases are involved in the rRNA modifications 
of about 200 nucleotides. 5S rRNA, synthesized in the nucleoplasm by a different 
enzyme, RNA Polymerase III, and ribosomal proteins, synthesized in the cytoplasm, are 
then recruited into the nucleolus to become integrated into preribosomal particles.  
The steps of the ribosome biogenesis occur in distinct compartments of the nucleolus, 
which can be distinguished by their morphology using electron microscopy: fibrillar 
centres (FCs), dense fibrillar components (DFCs) and granular components (GCs). 
Transcription of ribosomal rDNA repeats by RNA polymerase I occurs either at the 
boundary between the FC or in the  DFC alone (Derenzini et al. 2005; Boisvert et al. 
2007). The pre-ribosomal RNA transcripts are spliced and modified by small nucleolar 
ribonucleoproteins (snoRNPs) in the DFC. Final maturation of the pre-ribosomal 
ribonucleoprotein and assembly with ribosomal proteins occurs mostly in the GC 
region. In the GC, the 5.8S and 28S ribosomal RNAs (rRNAs) assemble with the 5S 
rRNA transcript to form the 60S subunit, whereas the 18S rRNA alone assembles into 
the 40S ribosome subunit. The 40S and 60S ribosome subunits are both exported to the 
cytoplasm, where they bind to mRNA to form functional ribosomes. (Tschochner and 
Hurt 2003; Derenzini et al. 2006). 
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Figure 3 A model for human ribosome biogenesis. Ribosome biogenesis requires coordinated 
expression of precursor 47S rRNA by RNA Pol I, RPs and auxiliary factors by RNA PolII, and 
5S RNA by RNA PolIII. Processing and assembly of the ribosomal subunits occur in the 
nucleolus, followed by export of the subunits and assembly into mature ribosomes in the 
cytoplasm.  
 
Although the best characterized function of the nucleolus is the ribosome biogenesis, 
several lines of evidence show that this dynamic organelle is involved in additional 
processes. Among these there are the regulation of mitosis, the cell-cycle progression 
and proliferation, tumorigenesis, aging, some forms of stress response in particular 
those involving p53 activation (Boisvert et al. 2007).   
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Ribosome biogenesis and cell proliferation 
 
The terms ‘growth’ and ‘proliferation’ have often been used interchangeably, without 
close attention to their actual meanings. Growth is an increase in cell mass and 
proliferation is an increase in cell number: they represent two distinct but 
interdependent events. In order to proliferate a cell must increase in size otherwise it 
will divide in ever smaller cells (Thomas 2000). This increase in cellular components 
requires an increase of protein synthesis which in turn requires new ribosomes. Given 
that the ribosome biogenesis has to precede the proliferative response, the first products 
of the protein-synthesis apparatus are the translational components themselves, most 
notably ribosomal proteins (Amaldi et al. 1997). As a consequence, ribosomal-protein 
messenger RNAs in proliferating cells have the added characteristic that they 
monopolize the cell’s translational capacity. In this way only when the cell has 
established a substantial capacity for protein synthesis the key components of the cell-
cycle control system can be synthesized (Thomas 2000). 
Given this strict relationship between ribosome biogenesis and proliferation and 
considering that making ribosomes consumes approximately 80% of the energy of a 
proliferating cell, it’s not surprising that ribosome biogenesis directly control cell cycle 
progression. Ribosome biogenesis rate influences the length of the G1 phase as 
observed in study of rat hepatoma cells treated with Actinomicyn D, a polypetdide 
antibiotics that selectively inhibit Polymerase I activity when used at low doses 
(Derenzini et al. 2005). Only when an adequate ribosome complement is achieved the 
cell can pass to the S phase. Indeed at the end of G1 phase, the restriction point defines 
a limit beyond which the cell is committed to divide independently of growth (Riddle et 
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al. 1979; Pardee 1989). Several studies demonstrated that the transcription activity of 
RNA Polymerase I was closely related to the cell doubling time (DT) in human cancer 
cell lines growing in vitro and in vivo: the greater the rRNA transcription rate, the 
shorter the cell DT (Derenzini et al. 1998, 2000). It’s now well established that the 
inhibition of the ribosome biogenesis cause the cell cycle arrest in the G1 phase in a 
p53/pRb dependent manner (Pestov 2001; Montanaro et. al. 2007). 
Cell cycle control elements can in turn affect ribosome biogenesis. Mitotic silencing of 
RNA Polymerase I transcription and reactivation during the transition from mitosis to 
the G1 phase of the cell cycle are controlled at multiple levels (Sirri 2002). 
Phosphorylation of SL1 by cdc2-cyclin B during metaphase correlates with the 
inactivation of SL1, an inability of SL1 to interact with UBF and mitotic repression of 
rDNA transcription. Therefore, productive pre-initiation complex formation, initiation 
and/or promoter escape and clearance might be down-regulated in mitosis. UBF 
inactivation during mitosis also correlates with its phosphorylation status (Grummt 
2003). Activation of rDNA transcription, upon serum stimulation of serum starved 
NIH3T3 cells, correlates with phosphorylation of UBF by the G1-specific complexes 
cyclin-dependent kinase cdk4-cyclin D1 and cdk2-cyclin E and cdk2-cyclin A required 
for the interaction of UBF with Pol I (Klein and Grummt 1999; Voit 1999). The tumor 
suppressors pRb and p53, master key in cell cycle regulation,  play an important role in 
the regulation of Pol I activity. Indeed they can directly interfering with the assembly of 
a productive transcriptional machinery on the rRNA promoter (Zhai 2000; Voit 1997). 
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The p53 tumor suppressor protein 
 
The discovery of p53 as a cellular SV40 large T antigen-binding protein in 1979 marks 
the beginning of a dynamic era in cancer research that was expected to have a major 
impact in the clinic. p53 has established itself as a key tumor suppressor, potent 
apoptosis-inducer, and prognostic marker in cancer. The p53 gene is mutated in around 
50% of human tumors (Soussi and Wiman 2007). This emphasizes the central role of 
the p53 pathway in regulation of cell growth and survival. Moreover, the p53 status of a 
tumor may have a strong influence on sensitivity to commonly used anticancer drugs 
and radiotherapy. The inactivation of p53 results in a failure to respond properly to a 
variety of stress signals, leading to increased genomic instability and eventually cancer 
(El-Deiry 1998). Although mice that are homozygous null for p53 are developmentally 
competent, they are highly predisposed to tumors, indicating that p53 has an important 
function in protecting cells against aberrant cell growth and neoplastic transformation 
(Donehower et al. 1992).  
p53 is a nuclear transcription factor that accumulates in response to cellular stress, 
including DNA damage and oncogene activation. Several forms of DNA damage have 
been shown to activate p53, including those generated by ionizing radiation (IR), radio-
mimetic drugs, ultraviolet light (UV) and chemicals. Recently, a new type of stress 
signal generated by disrupting ribosomal biogenesis and mediated by several ribosomal 
proteins has been shown to inhibit MDM2 and activate p53. Ribosomal biogenesis can 
be disrupted by serum starvation, depletion of nucleotides, agents such as Actinomycin 
D or 5-Fluorouracil, malfunction of nucleolar proteins involved in ribosome biogenesis 
(such as the dominant-negative mutant Bop1) (Pestov et al. 2001), inhibition of B23 
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(also known as nucleophosmin) activity by ARF (Itahana et al. 2003), and reduction of 
RPS6 (Fumagalli et al. 2009; Volarevic et al. 2000); all of these have been shown to 
generate nucleolar stress that signals to p53. This allows cells to halt proliferation under 
unhealthy and poor ribosomal biogenesis conditions. All these stimuli triggers 
transcriptional trans-activation of p53 target genes such as p21, GADD45, Bax, Puma, 
and Noxa, leading to cell cycle arrest, senescence and/or apoptosis (Vousden and Prives 
2009). MDM2 gene, whose protein product ubiquitinates p53 and targets it for 
proteasome-mediated degradation, is another p53 transcriptional target. Therefore, p53 
and MDM2 form a negative regulatory loop that down-regulates p53 expression. p53 
can also perform various functions in the cytoplasm (Green and Kroemer 2009). 
Translocation of p53 to mitochondria promotes apoptosis through transcription-
independent mechanisms (Mihara et al. 2003). Oncogene activation leads to aberrant 
DNA replication with stalled replication forks, which triggers a DNA damage response 
(DDR) involving activation of ATM and Chk2 kinases and accumulation of p53 
(Bartkova et al 2005; Gorgoulis et al. 2005). Oncogene activation may also induce 
expression of the p14Arf protein (p19Arf in the mouse) that inhibits MDM2, leading to 
p53 accumulation (Sherr and Weber 2000). Accumulation and activation of p53 triggers 
cellular senescence or cell death by apoptosis. Thus, activation of p53 upon oncogenic 
stress serves to eliminate nascent tumor cells by apoptosis and/or senescence, forming a 
critical barrier against tumor development.  
A vast majority of p53 mutations in human tumors are single missense mutations that 
cluster in the p53 core domain (residues 100–300) that recognizes p53 binding motifs in 
DNA (Hainaut and Wiman 2005). In general, mutant p53 proteins are deficient for 
specific DNA binding, arguing that DNA binding and transcriptional regulation of 
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target genes are crucial for p53-mediated tumor suppression (Soussi and Wiman 2007). 
Moreover, it is becoming increasingly clear that the mutations may endow p53 with 
various gain-of-function activities (Brosh and Rotter, 2009). These include for instance 
enhanced NF-kB activation (Weisz et al. 2007) and promotion of tumor invasion by 
affecting integrin and epidermal growth factor receptor (EGFR) trafficking (Muller et 
al. 2009). In addition in many different cancers p53 it’s rendered inactive by a range of 
indirect mechanisms like MDM2 amplification or loss of ARF (Olivier et al. 2004). 
An important role of p53 in processes such as cell cycle arrest, senescence and 
apoptosis is firmly established. However, recent studies have painted a more complex 
picture of p53 as regulator of diverse biological processes, such as autophagy, 
metabolism, and aging (Vousden and Prives 2009). It has been known for decades that 
cancer cells have changes in multiple metabolic pathways, including the usage of 
glycolysis also under conditions of normoxia. Such changes seem to support 
dysregulated cell growth, allow synthesis of macromolecules, and protect cancer cells 
from oxidative stress. Interestingly, p53 has been shown to have a direct impact on 
metabolism. Lack of nutrients or ‘‘metabolic stress” can induce a p53 response via 
activation of AMP-activated protein kinase (AMPK) and inhibition of the kinase AKT 
that promotes MDM2- mediated p53 degradation in the proteasome. This leads to 
upregulation of p53 target genes, among which TSC2 inhibits the mTOR protein that 
stimulates protein synthesis and inhibits autophagy, a process that leads to digestion of 
cellular components in lysosomes. As a consequence, cell growth is suppressed 
(Vousden and Ryan 2009). 
p53 can also regulate cellular redox status. High levels of p53 provide a pro-oxidant 
function through up-regulation of genes such as Bax, Puma, PIG3, and other genes, 
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resulting in the production of reactive oxygen species (ROS) (Bykov et al. 2009). In 
addition, p53 is itself regulated in a redox-dependent manner. Efficient p53 DNA 
binding requires a reducing environment. Another exciting aspect of p53 is its emerging 
role in aging and longevity. In vivo studies have indicated that overactive p53 can 
suppress tumor formation but also induce an early aging phenotype (Tyner et al. 2002). 
Considering the multiple roles of p53 in a wide range of biological processes and its 
ability to control life and death of cells, it is not surprising that p53 is tightly regulated. 
Having a short half-life, p53 is normally maintained at low levels in unstressed 
mammalian cells by continuous ubiquitylation and subsequent degradation by the 26S 
proteasome (Chene 2003). This is primarily due to the interaction of p53 with the ring-
finger ubiquitin E3 ligase MDM2. When the cell is confronted with stress, however, 
p53 ubiquitylation is suppressed and p53 is stabilized and accumulates in the nucleus, 
where it forms a homotetrameric complex (Yang et al. 2004). Only tetrameric p53 
seems to be fully active as a transcriptional activator or repressor of distinct target genes 
that contain p53 sequence-specific DNA binding sites. 
Active p53 is subject to a complex and diverse array of covalent post-translational 
modifications, which markedly influence the expression of p53 target genes. The most 
commonly reported post-translational modifications of p53 include phosphorylation and 
acetylation that generally result in p53 stabilization, accumulation and activation in the 
nucleus. (Vousden and Prives 2009). Post-translational control, rather  than 
transcriptional regulation of the p53 gene, provides a particularly rapid, sensitive and 
readily-reversible mechanism for regulating p53 activity (Bode and Dong 2004). 
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Nonetheless, recent studies have revealed critical regulatory circuits that target p53 at 
the RNA level via both RNA-binding proteins and regulatory RNAs. Proteins such as 
HuR, L26, RPL26, nucleolin, and Wig-1 (Zhang and Chen 2008,) can bind to the 50 or 
30 untranslated regions (UTR) of p53 mRNA and control its stability or translation 
through various mechanisms.  
 
 
Figure 4 Simplified scheme of the p53 pathway. The p53-MDM2 feedback is the “heart” of 
the p53 pathway. Under normal conditions, it maintains constantly low steady-state p53 levels 
and activity. Various stress signals impinge on this central loop to release p53 from MDM2-
mediated inhibition. It is generally believed that the nature of the phenotypic response to p53 
activation is at least partially proportionate to the amplitude, duration and nature of the 
activating signal. Severe stress induces more extreme, usually irreversible, responses namely 
apoptosis and senescence while milder stress leads to a transient growth arrest coupled to an 
attempt to deal with the cause of the stress and repair the damage caused by it. Recent evidences 
indicate that p53 has also an important role in enabling the cell to adjust its metabolism in 
response to mild normal physiological fluctuations, including those in glucose and other 
nutrients levels, oxygen availability and reactive oxygen species levels.  
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p53 and ribosome biogenesis control 
 
p53 protects against cancer through its capacity to induce cell cycle arrest or apoptosis 
under a large variety of cellular stresses. However, more than 20 years after the 
discovery of the protein, it is not known how such diversity of signals can be integrated 
by a single molecule. Numerous studies indicate that the common denominator of all 
p53-inducing stresses, is that they all cause nucleolar disruption and compromise 
nucleolar function. The nucleolus is thus a sensor responsive to a wide range of cellular 
stresses (Rubbi and Milner 2003). The proposed model predicts that p53 should be 
stabilized whenever nucleolar disruption occurs, even in the absence of DNA damage, 
of phosphorylation inhibition or of metabolic stresses. Strong evidence of the 
involvement of the ribosome biogenesis in p53 activation came from the observations 
on the nucleolar protein Bop1, implicated in pre-rRNA processing. When a dominant- 
negative Bop1 mutant was introduced into cells, it interfered with nucleolar function, 
inducing p53 stabilization and a p53-dependent cell cycle arrest in G1 (Pestov et al. 
2001). Moreover microinjection of antibodies against the nucleolar protein upstream 
binding factor (UBF) was sufficient to induce nucleolar disruption and induction of p53 
(Rubbi and Milner 2003). Available data indicate that the mechanism of p53 activation 
is mainly the consequence of changes in functional and physical interactions of the 
tumor suppressor with MDM2. Indeed disrupting the nucleolar structure would cause 
the release of several ribosomal proteins that bind to MDM2 and relieve its inhibitory 
activity toward p53 (Zhang and Lu 2009; Deisenroth and Zhang 2010). In response to 
nucleolar stress induced by a low dose of Actinomycin D (5 nM) (Dai and Lu 2004; Dai 
et al. 2004; Jin et al. 2004) and 5-Fluorouracil (Gilkes et al. 2006; Sun et al. 2007), by 
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serum depletion and contact inhibition (Bhat et al. 2004), by mycophenolic acid-
mediated depletion of GTP (Sun et al., 2008), or by interfering with nucleolar function 
via ectopic overexpression of nucleostemin (Dai et al. 2008), an increased binding of 
RPL5, RPL11, and RPL23 to MDM2 was observed. In addition to the three RPs, RPS7 
(Zhu et al., 2009), RPL26 (Ofir-Rosenfeld et al. 2008) and the nucleolar protein 
Nucleophosmin have also been shown to interact with MDM2. The correlation between 
impairment of nucleolar function and p53 stabilization can be extended further: 
mammalian cells lose their nucleoli during mitosis, and full nucleolar functionality, in 
the form of the maximum level of rRNA synthesis, is not achieved until late in G1 
phase (Klein and Grummt 1999). This period of recovery of nucleolar functionality is 
precisely the window in which p53 levels are increased during the cell cycle (David-
Pfeuty 1999). Moreover, agents that arrest cells in mitosis (e.g. nocodazole) induce a 
p53 response (Pluquet and Hainaut 2001) and at the same time prevent nucleolar 
reformation. 
The nucleolar disruption model of p53 stabilization offers a unifying explanation for the 
induction of p53 under a wide range of cellular stresses. However, according to this 
view, a stress must always acutely damage a fundamental cellular function in order to 
induce p53 activation, while it’s becoming clear that p53 activity may be far broader 
than simply to promote a tumor suppressive response to acute stress (Vousden and 
Prives 2009). Indeed, the ability to prevent cancer has been suggested to be an 
“evolutionarily late” cooption of p53 activities that had initially evolved to protect the 
germline and monitor development (Aranda-Anzaldo and Dent 2007; Vousden and 
Lane 2007). It is now becoming apparent that p53 functions are involved in diverse 
aspects of health and disease (Fig. 5) that do not require acute stress. Therefore, we 
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wondered whether quantitative alteration in the production of rRNA must necessarily 
disrupt the nucleolus and induce ribosomal protein leakage to stabilize and activate p53. 
For this purpose we induced a specific down-regulation of rRNA synthesis by silencing 
the RNA polymerase I catalytic subunit and then we up-regulated rRNA synthesis using 
three different experimental conditions. We found that quantitative variations in rRNA 
synthesis were able to influence p53 activity by altering the binding of MDM2 with the 
ribosomal proteins without inducing nucleolar disruption.  
 
 
Figure 5 p53 contributes to multiple normal processes and disease pathologies. In addition 
to its well-known role as a tumor suppressor, p53 also regulates other cellular (right) and 
developmental processes (left). These include processes that result in positive outcomes (red 
arrow) and those that result in diseases or other unfavorable outcomes (black arrow). Examples 
of p53 target genes (blue) that are regulated by p53 to produce the indicated cellular outcomes 
of p53 induction are shown. Note that, in many cases, numerous targets have been identified to 
mediate a specific outcome, even though only one example target gene is shown here.
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AIM OF THE THESIS 
 
Common denominator in the majority of p53-inducing stresses is nucleolar disruption. 
Alterations in the nucleolar structure lead to a release of ribosomal proteins to the 
nucleoplasm triggering their specific binding to MDM2, thus inhibiting MDM2’s E3 
ubiquitin ligase function toward p53 with consequent p53 stabilization and activation 
(Lindstrom et al., 2007). 
Purpose of our work was to assess whether this mechanism could be extended further 
and could be able to regulate p53 balance even in milder stressful conditions. We 
wonder whether quantitative alterations in the production of rRNA were sufficient to 
modulate p53 even in the absence of severe nucleolar alterations. We investigated the 
consequences of a selective down-regulation and up-regulation of rRNA synthesis on 
p53 level and activity. To down-regulate rRNA synthesis we decided to silencing the 
POLR1A, the RNA polymerase I catalytic subunit, obtaining a selective reduction of 
the 45S rRNA. In this condition we evaluated the level of p53 and the mechanism 
responsible of p53 regulation upon rRNA synthesis inhibition. In particular we focused 
our attention on the relationship between ribosomal proteins-MDM2-mediated p53 
stabilization. To up-regulate rRNA production we used three different experimental 
conditions: cancer cells treated with insulin or exposed to the insulin-like growth factor 
1, rat liver stimulated by cortisol and regenerating rat liver after partial hepatectomy. In 
all the conditions we performed a series of studies in order to elucidate whether the up-
regulation of rRNA synthesis was responsible of p53 change through the mechanism 
involving MDM2 binding with ribosomal proteins.
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MATERIALS AND METHODS 
 
Cell lines, culture conditions and drug treatments 
 
U2OS, HCT-116 and MCF7 human cancer-derived cell lines and H4-II-E-C3 rat 
hepatoma cell line were cultured in monolayer at 37°C in humidified atmosphere 
containing 5% CO2 in DMEM (Euroclone, Milan, Italy) supplemented with 10% Fetal 
Bovine Serum (FBS, Euroclone), except MCF7 cells, which were grown in RPMI 1640 
(Euroclone) plus 5% FBS (Euroclone). Rat hepatocytes were isolated as previously 
described (Derenzini and Moyne, 1978). Serum starvation was obtained by culturing 
cells in medium containing 0.2% FBS. Actinomycin D (BioVision) was used at a final 
concentration of 8 nM; 5-fluorouracil (Teva Pharma Italia, Milan, Italy) was used 75 
μM; Hydroxyurea (Sigma-Aldrich, Milan, Italy ) was used 3.4 μM; Gemcitabine 
(Gemzar 200mg; Eli Lilly Italia spa) was used at the concentration of 10 μg/ml; 
Rapamycin (Cell Signaling Technology, Beverly, MA, USA) was used 20 nM. α-
amanitin (Boehringer Mannheim, Mannheim, Germany) was dissolved in the culture 
medium at the concentration of 5μg/ml. Human recombinant Insulin-like Growth Factor 
(Sigma- Aldrich) was added to growth medium at a final concentration of 100 ng/mL; 
human recombinant insulin (NovoNordisk Farmaceutici, Rome, Italy) was used 40 nM 
in growth medium; the proteasome inhibitor MG-132 (Calbiochem, Merck, 
Nottingham, UK) was used at a final concentration of 10 μM; the ribosome inhibitor 
Cycloheximide (Sigma-Aldrich) was used at a concentration of 20 μg/mL. 
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Animals 
 
Four male Wistar rats (weighing 180–200 g) rats underwent partial (2/3) hepatectomy 
under anaesthesia, according to Higgins and Anderson (1931) and 3 rats were 
intraperitoneally injected with cortisol (Sigma-Aldrich) at the dose of 10 mg/100 g body 
weight. Hepatectomised rats were killed 12 hours after operation and 3 sham-operated 
rats were used as controls. Cortisol treated rats were killed 8 hours after drug injection 
and 3 rats injected with saline were used as controls. Experimental procedures were 
approved by the Ethical Committee of the University of Bologna. 
 
 
RNAi, plasmids and transfection reagents 
 
Select Stealth RNAi (Invitrogen, Carlsbad, UK) targeted against catalytic subunit of 
RNA Polymerase I (POLR1A) and siRNA against rpL11 (described in Barkic et al. 
2009, target sequence 1) were used, while Stealth RNAi Negative Control (Invitrogen) 
or a scrambled sequence siRNA were used to transfect controls, respectively. Cells were 
transfected with Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM medium 
(Invitrogen) accordingly to manufacturer’s procedures. 
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RNA extraction, reverse transcription and real time PCR 
 
Cells were harvested and total RNA extracted with TRI reagent (Ambion, Austin, TX, 
USA) according to manufacturer instructions. Whole cell RNA was quantified 
spectrophotometrically and 2μg of RNA for each sample were reverse transcribed using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA, USA) following the manufacturer’s protocol. The relative amounts of POLR1A , 
45S rRNA, rpL11, p21, Bax, PUMA, β-Glucuronidas (GUSb), rat 45S rRNA, p21, Bax, 
PUMA, β-actin and 18S RNAs were evaluated by Real Time PCR performed on an ABI 
Prism 7000 Sequence Detection System (Applied Biosystems) with the 2-ΔΔCT method 
(Livak and Schmittgen 2001). The mean ΔCT value of the control sample was used in 
each experiment to calculate the ΔΔCT value of samples replicates. POLR1A, p21 and 
the internal control GUSb mRNAs were quantified with TaQMan Gene Expression 
Assays primers and probe kits (Applied Biosystems); primers and UPL probe (Roche 
Diagnostics, Milan, Italy) for rpL11 and rpL5 were chosen with the Roche online 
primer design tool, primers for SYBR Green Real Time PCR analysis of human Bax, 
PUMA and rat p21, Bax, and PUMA were designed using the same online tool; primers 
for human and rat 45S rRNA have been already described in (Murayama et al. 2008) 
and (Grandori et al. 2005) respectively. All sequences are available upon request. 
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Isolation of polyribosomal mRNA 
 
Subconfluent cells were washed in PBS at 4°C. The cellular pellet was lysed in 2 
volumes of 10 mmol/L Tris-HCl (pH 7.4), 10 mmol/L NaCl, 3 mmol/L MgCl2 0.5% 
NP40 for 10 minutes at 4°C. The lysates were then centrifuged at 14,000 x g for 10 
minutes at 4°C and the supernatant was used for the isolation of polyribosomes. Lysates 
were stratified onto a 15% to 50% sucrose gradient in 30 mmol/L HEPES/KOH (pH 
7.5), 80 mmol/L KCl, 1.8 mmol/L Mg-cetate, and centrifuged at 4°C for 15 hours at 
40,000 x g. From gradients, 1-mL fractions were collected and their absorbance was 
read at 260 nm. Polyribosomal fractions were pooled and centrifuged at 100,000 x g for 
15 hours at 4°C. RNA was extracted from pellets using Trizol reagent. 
 
 
Electron microscopy 
 
Cells were immediately fixed in a solution of 4% formaldehyde in 0.1 M Sörensen 
buffer, pH 7.2 and postfixed in 1% osmium tetroxide in the same buffer. All the 
samples were dehydrated in alcohol and embedded in Epon. Ultrathin sections were 
double stained with uranyl acetate and lead citrate. 
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Immunofluorescence 
 
Cells grown on glass coverslips were fixed and permeabilised in PBS containing 2% 
paraformaldehyde and 1% Triton X-100 for 5 minutes at room temperature. Samples 
were incubated for 30 minutes in PBS plus 1% Bovine Serum Albumin (BSA) Sigma- 
Aldrich) to block unspecific binding before incubating with the primary antibody 
diluted in PBS 1% BSA overnight at 4°C. The samples were rinsed in PBS and then 
incubated with FITCconjugated anti-mouse secondary antibody (Dako, Glostrup, 
Denmark) for 45 min at 37°C in the dark in a humidified chamber. Mounting and nuclei 
counterstaining were performed using the “pro long antifade reagent with DAPI” 
(Molecular Probes, Invitrogen) and observed under a fluorescence microscope (Carl 
Zeiss). 
 
 
Analysis of rRNA synthesis by 5-fluorouridine incorporation 
 
Analysis of nascent rRNA was performed on cells grown on coverslips by incorporation 
of 5- fluorouridine accordingly to the method described in (Boisvert et el. 2000). 
Briefly, cells were incubated for 15 minutes in medium containing 2mM 5-fluorouridine 
(Sigma-Aldrich), then washed in cold PBS and fixed in 2% paraformaldehyde and 1% 
Triton X-100 for subsequent immunofluorescence, performed as described above, using 
a monoclonal antibody specific for 5- fluorouridine. 
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Western blotting 
 
Whole cell protein extracts and subsequent SDS-PAGE and immunoblot analyses were 
made as already described (Montanaro et al. 2007). Briefly, total cellular proteins were 
extracted in lysis buffer (KH2PO4 0.1M pH 7.5, NP-40 1%, added with Complete 
protease inhibitors cocktail (Roche Diagnostics) and 0.1 mM β-glycerolphosphate) and 
quantified spectrophotometrically with the Bio-Rad Protein Assay (Bio-Rad 
Laboratories, Hempstead, UK). Nuclear proteins fraction for Western blot analysis was 
obtained accordingly to the method described in (Abmayr et al. 2006) with slight 
modifications. Proteins immobilized on nitrocellulose membranes (GE-Healthcare) 
were blotted overnight at 4 °C with primary antibody. Horseradish peroxidase-
conjugated secondary antibody were from Santa Cruz Biotechnology (Santa Cruz 
Biotechnology, CA, USA) and GE-Healthcare (anti-mouse). 
 
 
Immunoprecipitation 
 
Cells were lysed in buffer containing 50 mM Tris/HCl (pH 8.0), 150 mM NaCl, 0.8% 
NP40, 1mM DTT, 1mM EDTA and Complete protease inhibitors cocktail (Roche 
Diagnostics). For each sample, 2.0 mg of proteins were pre-cleared with Protein A/G 
PLUS-Agarose beads (Santa Cruz Biotechnology) at 4 °C for 30 minutes and 
subsequently incubated for 6 hours at 4 °C with anti-MDM2 polyclonal antibodies. The 
immunocomplexes were then precipitated with Protein A/G PLUS-Agarose beads for 2 
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hours at 4 °C, The beads were then centrifuged, washed four times in lysis buffer and 
resuspended in Laemmli buffer for subsequent immunoblot analysis. 
 
 
Antibodies 
 
Antibodies used in this work: mouse monoclonal anti-p53 (clone BP53-12, Novocastra 
Laboratories, Newcastle upon Tyne, UK), anti-p21 (clone SX118, Dako), anti-β-actin 
(clone AC-74, Sigma-Aldrich), anti-Nucleophosmin (clone Fc-61991, Zymed 
Laboratories, San Francisco, CA), anti-MDM2 (clone SMP14, Santa Cruz 
Biotechnology), anti-ribosomal protein S14 (a gift from U. Scheer, described in (Kruger 
et al. 2007), anti-halogenated uridine (BU-33, Sigma-Aldrich), rabbit polyclonal anti-
ribosomal proteins L11 and L5 (Panic et al. 2007), anti-MDM2 (H- 221, Santa Cruz 
Biotechnology), goat polyclonal anti-Lamin B (C-20, Santa Cruz Biotechnology). 
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RESULTS 
 
POLR1A silencing causes rRNA synthesis reduction and 
stabilizes p53 
 
In order to selectively inhibit the rRNA production we silenced the POLR1A gene by 
the siRNA procedure. A preliminary study demonstrated that in human cancer cell lines 
the silencing of the POLR1A gene by the siRNA procedure inhibited the expression of 
POLR1A mRNA and gave rise to a specific inhibition of rRNA synthesis (Donati et al. 
2010). The Polymerase I reduction, analyzed by Real Time PCR,  was observed 24 
hours after POLR1A siRNA and was still evident after 96 hours (Fig. 6A). 
POLR1A silencing caused a progressive reduction in the synthesis of rRNA in U2OS 
human cancer cells as measured by Real Time PCR evaluation of the 45S rRNA (Fig. 
6B).  rRNA synthesis was also evaluated by 5-fluorouridine nucleolar incorporation. 
Immunofluorescence analysis revealed that, 48 hours after POLR1A siRNA, 
fluorouridine incorporation in the nucleoli  was reduced in comparison with control 
cells, after 72 hours only a few foci in the nucleolar peripheral area showed 
fluorouridine incorporation (Fig. 6C). We also used the silver staining to evaluate 
nucleolar activity, this technique revealed a reduction in the number of the nucleoli in 
cells where Polimerase I was silenced (Fig. 6D).  
We observed that in consequence of rRNA synthesis reduction p53 level was increased. 
The p53 accumulation level paralleled the reduction of rRNA synthesis. We found that 
p53 was accumulated as early as 24 hours after the end of the POLR1A silencing 
                                                                                                         RESULTS 
25 
 
procedure and its amount was increased in 48 hour-silenced cells, as revealed by 
Western blot analysis (Fig. 7).  
 
 
Figure 6 POLR1A silencing down-regulates rRNA synthesis. A, Real Time PCR analysis of 
POLR1A levels in U2OS cells after 24, 48 and 96 hours the siRNA procedure. B, Real Time 
PCR analysis of 45S rRNA in POLR1A silenced cells. C, immunofluorescence analysis of 
fluorouridine incorporation in nucleoli of POLR1A-silenced cells. D, silver staining of NORs in 
control and U2OS cells, 72 hours after POLR1A silencing. 
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Figure 7 POLR1A silencing stabilizes p53. Western blot and densitometric analysis of p53 
level in U2OS cells after 24 and 48 hours POLR1A silencing. 
 
 
p53 stabilization after POLR1A silencing doesn’t require the 
disruption of  the nucleolar structure 
 
48 hours after POLR1A silencing, electron microscopy (Fig. 9A) showed that, in 
comparison with U2OS cells transfected with control sequences, the nucleoli of 
POLR1A-silenced cells appeared to be smaller in size with a reduced amount of fibrillar 
components (fibrillar centres plus the associated dense fibrillar component) which 
represent the structural-functional units of the nucleolus (Montanaro et al. 2008). 
However, the ribonucleoprotein components did not exhibit any change, such as 
segregation or fragmentation (examples shown in Fig. 8), of their distribution within the 
nucleolar body, which are indicative of disrupted nucleolar structure. Since 
nucleophosmin translocation from the nucleolus to the nucleoplasm is considered to 
represent a marker of nucleolar changes (Chan et al. 1996), we analyzed the distribution 
of nucleophosmin in 48 hour-POLR1A-silenced cells. We found that after POLR1A 
silencing only a reduction of the immuno-cytochemical labeling of nucleophosmin was 
observed in nucleoli without any diffusion of the protein to the nucleoplasmic 
compartment (Fig. 9B). Lastly, we wondered whether POLR1A silencing induced 
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changes in the location of ribonucleoproteins to the nucleolus. We analyzed the 
distribution of the rpS14, a ribosomal protein incorporated early in ribosome formation 
(Kruger et al. 2007). 48 hours after the end of POLR1A silencing procedure no 
translocation of rpS14 from the nucleolus to the nucleoplasm was detected in U2OS 
cells (Fig. 9C). All together these data led us to conclude that the inhibition of rRNA 
synthesis by POLR1A silencing induced p53 stabilization without any evidence of 
nucleolar disruption and nucleolar protein leakage. 
In order to extend our analysis to the relationship among rRNA synthesis inhibition, 
nucleolar disruption and p53 stabilization, we also evaluated the effect of 5-Fluorouracil 
exposure on p53 expression and nucleolar structural organization in U2OS cells. The 
reduction of rRNA synthesis induced by the drug was associated with p53 stabilization 
without alteration, once again, in the nucleolar ultrastructural morphology and 
nucleophosmin translocation to the nucleoplasm (Fig. 10). 
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Figure 8 Ultrastructural patterns of the “nucleolar disruption”. A U2OS cell after 4 h 
exposure to 8 nM Actinomycin D. The ribonucleoprotein structure of the nucleolus appear to be 
segregated into three main components: a light fibrillar, a dense fibrillar and a granular 
component. Uranium and lead staining. B, Isolated rat hepatocyte treated with α- amanitin at the 
dose of 5μg/ml for 3 h. The nucleolar body appears to be disrupted into three fragments in 
which the ribonucleoprotein components are segregated. Uranium and lead staining. Scale bar, 
0.5 μm. 
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Figure 9 Nucleolar structure is preserved after POLR1A silencing. A, Electron microscopy 
visualization of nucleolar structural organization in control and POLR1A-silenced U2OS cells, 
48 h after the silencing procedure. Arrows indicate the fibrillar centres, surrounded by the 
ribonucleoprotein fibrillar and granular component. B, Visualisation of nucleophosmin (NPM) 
distribution in control and 48 h POLR1A-silenced U2OS cells. Cells were labeled with 
monoclonal antibodies versus nucleophosmin; the antibodies were revealed by FITCH-
conjugated secondary antibodies. Nuclei were stained with DAPI (DAPI). C, Visualization of rp 
S14 distribution in control and 48 h POLR1Asilenced U2OS cells. Cells were labeled with 
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antiribosomal protein S14 antibodies; the antibodies were revealed by FITCH-conjugated 
secondary antibodies. DAPI nuclear staining. Scale bar, 10 μm. 
 
 
Figure 10 Fluorouracil inhibits the synthesis of rRNA and stabilizes p53 without inducing 
the “nucleolar disruption”. A, Representative Western blot of p53 expression in U2OS cell 
exposed to 75 μM 5-fluorouracil for 4 h. Ctrl, control cells; +5FU, cells treated with the drug. B, 
Quantitative analysis of 28S and 18S rRNA of control and 5FU- treated U2OS cells. RNA was 
size-separated on 1% agarose gel and stained with ethidium bromide. Two bands corresponding 
to 28S and 18S rRNA were visible in each lane. Histograms show the values (mean ± s.d.) of 
three experiments. C, Nucleolar fine structural organization of a U2OS cell, treated with 5FU. 
Arrows indicate the fibrillar centres, surrounded by the ribonucleoprotein fibrillar and granular 
component. Uranium and lead staining. Scale bar, 0.4 μm. D, Visualization of nucleophosmin 
distribution in U2OS cells treated with 5-FU: 1) DAPI staining, 2) nucleophosmin labeling with 
monoclonal antibodies versus nucleophosmin, revealed by FITCH-conjugated secondary 
antibodies 3) merging of image 1 and 2. Scale bar, 10 μm. 
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p53 stabilization after POLR1A silencing is due to MDM2 
inactivation by ribosomal proteins 
 
p53 levels are mainly regulated by the ubiquitine ligase MDM2. Alterations in the 
ribosome biogenesis are sensed by p53 by interfering with Mdm2 mediated degradation 
(Momand et al. 1992; Haupt et al. 1997; Kubbutat et al. 1997). Ribosomal proteins can 
in fact inhibit Mdm2 function after a perturbation of ribosome biogenesis, thus leading 
to p53 stabilization and activation (Zhang and Lu 2009); therefore we wondered 
whether the reduction of rRNA synthesis induced by POLR1A silencing caused p53 
stabilization following the same mechanism. 
First we wanted to evaluate if a reduced proteasome mediated degradation was 
responsible for the increased p53 levels in POLR1A silenced cells. In order to do this we 
first evaluated the half-life of p53 by time course Western blot analysis in control and 
POLR1A-silenced U2OS cells after treatment with Cycloheximide at a dose capable of 
completely inhibiting protein synthesis. We found that the half-life of p53 in POLR1A-
silenced cells was longer than that of control cells (Fig. 11A). The involvement of 
proteasome was demonstrated by blocking the proteasome activity with the small 
inhibitor molecule MG-132. After inhibiting p53 degradation with MG-132 we 
observed that the level of p53 in POLR1A-silenced cells for the time-intervals 
considered did not change while it progressively increased in control cells, as evaluated 
by Western blot analysis (Fig. 11B).  
To understand the mechanism involves in regulating p53 levels after POLR1A silencing, 
we wonder whether POLR1A silencing induced quantitative alterations also in the 
ribosomal proteins. Real Time PCR analysis showed that the level of the rpL5 and 
                                                                                                         RESULTS 
32 
 
rpL11 mRNAs associated to polyribosomal fractions was similar both in control and in 
48 h-POLR1A-silenced cells (Fig. 12A), demonstrating that POLR1A interference did 
not induce variations in rpL5 and rpL11 synthesis. At this point we looked for 
quantitative changes in the binding of rpL5 and rpL11 to MDM2 by co-
immunoprecipitation analysis. We observed that the amount of both proteins co-
immunoprecipitated with MDM2 increased in POLR1A-silenced cells in comparison 
with control cells (Fig. 12B).  
We demonstrated the importance of the ribosomal proteins in determining p53 
stabilization after POLR1A silencing by observation in RPL11-silenced cells. We 
silenced RPL11 alone, or both RPL11 and POLR1A; the silencing strongly reduced the 
expression of the relative mRNAs (Fig. 12C). Western blot analysis of p53 expression 
showed that POLR1A interference did not stabilize the protein in RPL11-silenced cells 
(Fig. 12D), thus demonstrating that rpL11 availability was necessary for p53 
stabilization in POLR1A-silenced cells. 
Other experimental models showed that p53 stabilization in POLR1A-silenced cells was 
due to the inactivation of MDM2 consequent to its nucleolar sequestration (Lohrum et 
al 2003; Bernardi et al. 2004). In order to exclude this, we evaluated the distribution of 
MDM2 in control and POLR1A-silenced U2OS cells by immunocytochemistry. We 
found that POLR1A silencing did not induce any accumulation of MDM2 in nucleoli 
(Fig. 13). Therefore, all together these data were consistent with a ribosomal-protein 
mediated mechanism of p53 stabilization after rRNA synthesis down-regulation. 
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Figure 11 Reduced proteasome mediated degradation is responsible for the increased p53 
levels in POLR1A-silenced cells. A, Time course analysis of p53 protein expression in control 
and POLR1A-silenced U2OS cells, 48 h after the silencing procedure, exposed to 
Cycloheximide (CHX) at a concentration of 20 μg/mL. B, Time course analysis of p53 protein 
expression in control and POLR1A-silenced U2OS cells, 48 h after the silencing procedure, 
exposed to the proteasomal inhibitor MG- 132 at the concentration of 10 μM, for 2 hours.  
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Figure 12 MDM2 inactivation by ribosomal proteins is responsible for p53 stabilization 
after rRNA synthesis up-regulation. A, Polysomal profiles and relative changes of the total 
amount of rpL11 and rpL5 mRNAs associated with polysomal fractions from control and 
POLR1A-silenced cells. B, Western blot of the amount of rpL5 and rpL11 bound to MDM2 in 
control and POLR1A-silenced U2OS cells, 48 h after the silencing procedure. Input, amount of 
rpL5, rpL11 and MDM2 before the immunoprecipitation; IP:MDM2, amount of rpL5, rpL11 
and MDM2 after the immunoprecipitation with MDM2 antibody. C, Real Time PCR analysis of 
rpL11 and POLR1A mRNA in control and in U2OS cells silenced for either RPL11 alone or 
both RPL11 and POLR1A expression (POLI-). D, Western blot of p53 expression in control and 
POLR1A-silenced cells, either or not silenced for rpL11 expression. 
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Figure 13 POLR1A interference does not modify the distribution of MDM2 in the U2OS 
cell nuclei. Distribution of MDM2 in control and in POLR1A-silenced U2OS cells, 48 hours 
after the end of the silencing procedure, as visualized by anti-MDM2 rabbit polyclonal antibody 
immunostaining revealed by FITCH-conjugated secondary antibodies. Scale bar, 10 μm. 
 
 
 
 
The contemporary reduction of rRNA and protein synthesis 
does not stabilize p53 
 
Our results strongly suggest that the increased p53 levels consequent the rRNA 
synthesis down-regulation is due to a reduced protein degradation mediated by MDM2 
that, in turn, is due to an increased availability of ribosome free-protein that bind and 
inhibit MDM2. To further demonstrate this mechanism we wondered what happened to 
p53 when both rRNA and protein synthesis are down-regulated. For this purpose we 
used either the serum starvation procedure or the Rapamycin treatment. The amount of 
45S rRNA, detected by RT-PCR analysis after 24 hours of serum starvation, was 
reduced in U2OS cells (Fig. 14A) as well as 5-fluorouridine incorporation into nucleolar 
rRNA detected by immunofluorescence (Fig. 14B). Evaluation of p53 by Western blot 
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analysis showed a reduction (Fig. 14C). At that time, the translation level of the rpL5 
and rpL11 mRNAs was also markedly reduced (Fig. 14D), as well as the nuclear 
amount of these proteins (Fig. 14E). Regarding the experiments with Rapamycin, MCF-
7 cells were used because of the very low sensitivity of the U2OS cell to the drug 
exposure. Treatment with 20 nM Rapamycin for 24 hours strongly reduced both the 
amount of 45S rRNA as detected by RT-PCR analysis (Fig. 15A) and the nucleolar 5-
fluorouridine immunofluorescent staining (Fig. 15B). Rapamycin treated cells showed a 
reduction in p53 expression (Fig. 15C) and in the translation of the rpL5 and rpL11 
mRNAs (Fig. 15D). Therefore both experimental conditions, serum starvation and 
Rapamycin treatment, conducted for a period of 24 hours were able to induce a 
reduction of rRNA and ribosomal protein synthesis. In this conditions we couldn’t 
observe an increase in p53 expression levels as previously observed in consequence of 
rRNA down-regulation alone; in this case p53 levels were reduced likely as a 
consequence of the reduced p53 mRNA translation.  
Given the above results we wondered what happened to p53 levels in POLR1A-silenced 
cells after serum starvation. We found that serum starvation prevented p53 
accumulation also in POLR1A-silenced cells, thus indicating that p53 accumulation 
after the inhibition of rRNA synthesis by POLR1A interference was strictly dependent 
upon availability of newly synthesized ribosomal proteins (Fig. 16). To exclude the 
possibility that the reduced p53 levels observed in this experimental condition was not 
due to a reduced p53 protein synthesis induced by the serum starvation, we decided to 
performed a further experiments using Actinomycin D (ActD). ActD selectively inhibits 
rRNA transcription (Montanaro et al. 2007) and disrupts the nucleolar structure causing 
ribosomal protein leakage from the nucleolus to the nucleoplasm (Rubbi and Milner 
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2003) when used at low doses. Serum-starved and Rapamycin-treated cells, analyzed by 
5-fluorouridine immunofluorescence staining, showed a complete inhibition of rRNA 
transcription when treated with ActD (Fig. 17). In ActD exposed cells p53 accumulation 
occurred again as observed by Western blot analysis (Fig. 18). The increased p53 levels 
were very likely a consequence of MDM2 inactivation caused by the released nucleolar 
ribosomal proteins. 
Therefore, all together these results led us to conclude that p53 stabilization after the 
reduction of rRNA synthesis by POLR1A interference was actually due to a relatively 
increased availability of ribosomal proteins for MDM2 binding as a consequence of 
their reduced use in ribosome building. 
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Figure 14 Serum starvation reduces both rRNA synthesis and ribosomal protein 
production and does not stabilize p53. A, Real-time RT-PCR analysis of the 45S rRNA 
expression and visualization of rRNA synthesis in control and serum-starved (starv) 
U2OS cells. Cell were starved for 24 h. B, to visualize rRNA synthesis cells were 
labeled with 5-fluorouridine for 15 min, and 5-fluorouridine revealed by specific 
FITCH-conjugated monoclonal antibodies. DAPI counter-staining. Scale bar, 10 μm. C, 
Representative Western blot and densitometric analysis of p53 expression in control and 
24 h serum-starved U2OS cells. D, representative polysomal profiles (left) and relative 
changes of the total amount of rpL11 and rpL5 mRNAs (right) associated to polysomal 
fractions from control and 24 h serum starved U2OS cells. E, representative Western 
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blot of the nuclear amount of rpL5 and rpL11 in control and 24 h serum-starved U2OS 
cells.   
 
Figure 15 Rapamycin treatment reduces both rRNA synthesis and ribosomal protein 
production and does not stabilize p53. A, Real-time RT-PCR analysis of the 45S rRNA 
expression and visualisation of rRNA synthesis in control and Rapamycin-treated (+Rapa) 
MCF-7 cells. Rapamycin was used at a concentration of 20 nM for 24 h. B, Cells were labeled 
with 5-fluorouridine for 30 min, and 5-fluorouridine revealed by specific FITCH-conjugated 
monoclonal antibodies. DAPI counter-staining. Scale bar, 10 μm. C, Representative Western 
blot and densitometric analysis of p53 expression in control and Rapamycin-treated MCF-7 
cells. D, Representative polysomal profiles (left) and relative changes of the total amount of 
rpL11 and rpL5 mRNAs (right) associated with polysomal fractions from control and 
Rapamycin-treated (+Rapa) MCF-7 cells. 
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Figure 16 Serum starvation prevents p53 accumulation also in POLR1A-silenced U2OS 
cells. Western blot analysis of p53 level in POLR1A-silenced and control U2OS cells, in normal 
growing medium or 24 hours after serum starvation. 
 
 
Figure 17 Actinomycin D treatment abolishes rRNA transcription in U2OS serum-starved 
cells. Serum-starved U2OS cells were exposed to 8 nM Actinomycin D for 4 h. 1) DAPI 
staining reveals unstained round structures corresponding to nucleolar bodies. 2) 5-fluorouridine 
immunofluorescent staining is uniformly distributed through the nucleoplasm, but not in the 
nucleolar bodies which are unlabelled. 3) Merging of image 1 and 2. Scale bar, 10 μm. 
 
 
Figure 18 Effect of Actinomycin D on serum starved and Rapamycin treated cells. Western 
blot analysis of p53 level in serum starved U2OS and Rapamycin treated MCF-7 cells exposed 
to 8 nM Actinomycin D. 
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rRNA synthesis up-regulation reduces p53 expression levels 
 
Considering the results observed in consequence of a selective reduction of the rRNA 
synthesis on p53 expression level, we wondered whether an up-regulation of rRNA 
synthesis was able to influence p53 level. To study the effect of a stimulation of rRNA 
synthesis on p53 stabilization we used three different experimental conditions: 1) cancer 
cell lines exposed either to insulin or to the insulin-like growth factor-1 (IGF-1), 2) 
regenerating rat liver after partial hepatectomy, and 3) rat liver after intra-peritoneal 
cortisol injection. Insulin and IGF-1 stimulate the activity of polymerase I transcription 
by elevating both UBF protein level and phosphorylation (Hannan et al. 1998). Partial 
hepatectomy induces a progressive increase in rRNA synthesis (up to 24 hours after 
operation) in regenerating rat hepatocytes (Sirri et al. 1995) very likely due to the 
induction of c-myc (Thompson et al. 1986) which controls the RNA polymerase I 
activity (Arabi et al. 2005; Grandori et al. 2005). Cortisol at the dose used in the present 
experiments stimulated rRNA transcription in rat hepatocytes (Sirri et al. 1995) by 
activating the glycocorticoid receptor signaling (Glibetic et al. 1993), while inhibiting 
their proliferation (Nadal 1995). 
We first evaluated the effect of an increase in rRNA synthesis in cancer cell lines: 
MCF-7 and H4-II-E-C3 cells. We used insulin to stimulate rRNA synthesis in H4-II-E-
C3 hepatoma cells, while MCF-7 mammary carcinoma cells that showed no response to 
the hormone were stimulated with Insulin Like Growth Factor 1(IGF-1). The evaluation 
of rRNA transcription by real time RT-PCR analysis of 45S rRNA indicated that rRNA 
synthesis was significantly increased in MCF-7 cells exposed to IGF-1 and in H4-II-E-
C3 cells treated with insulin, after 12 hours following the administration (Fig. 19A). In 
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all these experimental conditions we found that the expression of p53, as measured by 
Western blot analysis, was reduced in cells in which rRNA synthesis was stimulated in 
comparison to the relevant controls (Fig. 19B).  
Since in the above reported experimental conditions a series of signaling pathways are 
activated that might led to p53 down-regulation independent of rRNA synthesis 
stimulation, we evaluated the effect of IGF-1 stimulation on p53 expression in MCF-7 
cells after 48 h POLR1A silencing. We found that the synthesis of rRNA was down-
regulated both in control and IGF-1 treated cells silenced for POLR1A expression as 
evaluated by Real Time PCR analysis of 45S rRNA. IGF-1 exposure did not modify the 
level of p53 expression in POLR1A-silenced cells, thus indicating the key role of rRNA 
synthesis up-regulation in determining the reduction of p53 expression after IGF-1 
stimulation (Fig 20). 
Then we analyzed the consequences of rRNA synthesis stimulation in two different in 
vivo experimental conditions: regenerating rat liver after partial hepatectomy and rat 
liver after intra-peritoneal cortisol injection. Both the experimental conditions were 
efficient in inducing the increase in the amount of rRNA in comparison with the normal 
liver. The evaluation by Real Time PCR analysis of 45S rRNA showed an increase in 
the rRNA 12 hours after partial hepatectomy and 8 hours after intra-peritoneal hormone 
administration (Fig. 21A). Western blot analysis of p53 expression levels confirmed the 
reduction of the oncosuppressor previously observed in the cell lines, in the 
experimental conditions in which rRNA synthesis was stimulated (Fig. 21B).  
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Figure 19  rRNA synthesis up-regulation causes p53 reduction in cancer cell lines. A, Real 
Time PCR analysis of 45S rRNA 12 hours after IGF or Insulin administration in MCF-7 and  
H4-II-E-C3 cells respectively. B, p53 levels analyzed by Western blot in control and stimulated 
cells.  
 
 
Figure 20 IGF-1 exposure does not modify the level of p53 in POLR1A-silenced cells. Left 
panel shows a real-time RT-PCR analysis of the 45S rRNA expression in control, in 48 h-
POLR1Asilenced and in POLR1A-silenced MCF-7 cells exposed to IGF-1 at a dose of 100 
ng/ml for 12 h. The right panel shows a representative Western blot of p53 expression of MCF-
7 cells in the same experimental conditions as in the left panel. Histograms show the values 
(mean ± s.d.) of three experiments. 
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Figure 21  rRNA synthesis up-regulation causes p53 reduction in rats. A, Real Time PCR 
analysis of 45S rRNA in control rat liver, in regenerating rat liver 12 h after partial hepatectomy 
and in rat liver 8 h after cortisol intra-peritoneal injection at the dose of 10 mg/100 g body 
weight.. B, p53 levels analyzed by Western blot in control and treated animals.  
 
 
 
Increased proteasome degradation is responsible for p53 
reduction after rRNA synthesis stimulation 
 
In order to investigate the mechanism involved in the reduction of the p53 level after 
stimulation of rRNA synthesis we first analyzed the expression of the p53 mRNA in the 
MCF-7 cells exposed to IGF-1, the H4-II-E-C3 cells treated with insulin, the 
regenerating rat liver and the rat liver after cortisol treatment. The evaluation of the p53 
mRNA expression by Real Time PCR analysis indicated that, in all the experimental 
conditions of rRNA synthesis stimulation, no quantitative changes in TP53 transcription 
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occurred (Fig. 22). Therefore, we considered the possibility that the reduced level of 
p53 might be due to its increased proteasomal degradation. For this reason we treated 
both IGF-1-stimulated MCF-7 cells and insulin-exposed H4-II-E-C3 cells with the 
proteasome inhibitor MG-132. We found that, in both experimental conditions, the 
inhibition of proteasomal degradation cancelled the difference between the p53 
expression of control and stimulated cells, as evaluated by Western blot analysis (Fig. 
23). This data clearly indicated that the changes in p53 level were actually due to an 
increased protein degradation.  
 
Figure 22 p53 transcription is not altered after rRNA synthesis stimulation.  Real Time 
PCR analysis of p53 transcription level in control MCF-7 and H4-II-E-C3 cells and treated with 
12 hours IGF or insulin,  and in control, hepatectomized and cortisol treated  rat liver. 
 
Figure 23  Increased protein degradation is involved in regulating p53 level after rRNA 
up-regulation. Representative Western blot of the effect of 2 h treatment with the proteasomal 
inhibitor MG-132 at the concentration of 10 μM, on p53 expression in MCF-7 either or not 
stimulated by IGF-1 (p53.1: long exposure; p53.2: short exposure) and in H4IIEC3 cells either 
or not stimulated by insulin. 
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p53 reduction after rRNA synthesis up-regulation involves 
MDM2 inactivation with ribosomal proteins 
 
p53 expression levels are controlled by a mechanism that involves MDM2. We 
previously demonstrated the involvement of MDM2 increased binding to the ribosomal 
proteins in increasing p53 levels after selective reduction of rRNA synthesis. Therefore 
we wonder whether the same mechanism might regulate p53 level after a stimulation of 
rRNA synthesis. We performed co-immunoprecipitation analysis to evaluate the 
quantitative changes of two ribosomal proteins bound to MDM2 after rRNA synthesis 
stimulation. We found that the amount of the ribosomal proteins rpL5 and rpL11 co-
immunoprecipitated with MDM2 was reduced both in IGF-1-stimulated MCF-7 cells 
and in insulin-exposed H4-II-E-C3 cells in comparison to control cells (Fig. 24A), thus 
demonstrating that the same mechanism observed in consequence of a reduction of the 
synthesis of rRNA was valid even when the rRNA synthesis is stimulated. To 
demonstrate that the reduced binding of the analyzed ribosomal protein to MDM2 
wasn’t the consequence of a reduced protein synthesis, we analyzed the rpL5 and rpL11 
mRNAs bound to polyribosomes. The analysis performed by Real Time PCR showed 
an increase of the level of rpL11 mRNA in stimulated versus control cells (Fig. 24B), 
whereas we noticed no significant changes in the rpL5 mRNA level. 
To better define the mechanism of p53 stabilization after rRNA up-regulation, we 
performed experiments with the MDM2 inhibitor Nutlin-3 in control and IGF-
stimulated MCF7 cells. Nutlin-3 binds MDM2 in the p53-binding pocket, thus 
inhibiting MDM2-mediated p53 degradation and resulting in p53 stabilization (Vassilev 
et al. 2004). Western blot analysis of p53 expression after Nutlin-3 exposure indicated 
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that p53 stabilization was similar both in control and IGF-1-stimulated MCF-7 cells 
(Fig. 25). This strongly suggested that the reduction of p53 expression after stimulation 
of rRNA synthesis was actually the consequence of an increased binding of MDM2 to 
p53. 
 
 
Figure 24 After rRNA synthesis up-regulation the binding between the ribosomal proteins 
and MDM2 is reduced. A,  Western blot analysis of the amount of rpL5 and rpL11 bound to 
MDM2 in control and IGF treated MCF7 cells, 12 h after IGF administration. Input, amount of 
rpL5, rpL11 and MDM2 before the immunoprecipitation; IP:MDM2, amount of rpL5, rpL11 
and MDM2 after the immunoprecipitation with MDM2 antibody. B, Polysomal profiles and 
Real Time PCR analysis of the total amount of rpL11 and rpL5 mRNAs associated with 
polysomal fractions from control and IGF treated MCF7 cells.  
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Figure 25 After Nutlin-3 treatment p53 level is the same in control and IGF-stimulated 
cells. MCF-7 cells stimulated by IGF-1 and treated with Nutlin-3 at the concentration of 5 μM 
for 16 hours: A, Western blot analysis of p53 expression. B, Real-time RT-PCR analysis of p21 
mRNA expression. 
 
 
p53 target genes expression is reduced after rRNA synthesis 
up-regulation 
 
The observation that the level of p53 was reduced in cells in which the rRNA synthesis 
was stimulated prompted us to investigate whether the activity of p53 was also reduced 
in these cells. In order to evaluate p53 function we analyzed the expression of three p53-
target genes. We chose genes whose products have a tumor suppressor function: p21, 
BAX, PUMA (Burns and El-Deiry 1999; Sax and El-Deiry 2003). We analyzed the 
mRNA expression level of these target genes by Real Time PCR. In MCF-7 and H4-II-
E-C3 cancer cell lines the expression level of all the analyzed genes resulted 
significantly reduced when the rRNA was up-regulated by IGF and insulin stimulation 
respectively (Fig. 26). 
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Regarding the regenerating rat liver and the rat liver after cortisol treatment we 
observed a reduction only in BAX and PUMA expression level. p21 mRNA expression 
appeared to be reduced only in cortisol treated tissue, in fact in the regenerating rat liver 
p21 expression level was highly increased in comparison with control and resting liver 
(Fig. 26B). This  observation is consistent with previous data showing that in 
regenerating hepatocytes after partial hepatectomy the p21 mRNA was up-regulated 
with enhanced expression during G1 phase (Albrecht et al. 1997). For this reason we 
used regenerating rat livers which are in G1 phase, 12 hours after partial hepatectomy, 
while the synthesis of DNA began only 15 hours after surgery (Sirri et al. 1995). 
 
 
Figure 26 p53 target genes expression is reduced when the rRNA synthesis is up regulated. 
A, Real-time RT-PCR analysis of the mRNA expression of the three p53-target genes (p21, Bax 
and Puma) in control and MCF-7 cells exposed to IGF-1 for 12 h; in control and in H4IIEC3 
cells stimulated by insulin for 16 h; B, in control and in regenerating and cortisol-stimulated rat 
liver. Histograms show the values (mean ± s.d.) of three experiments. 
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p53 function after drug-induced stress is impaired when 
rRNA synthesis is increased 
 
During the normal cell growth p53 function is not required, its activation is necessary 
only in response to stresses when p53 levels and p53 ability to activate the transcription 
of its target genes are increased. For this reason we wondered whether the reduced p53 
level in cells with increased rRNA synthesis might also be reflected in a reduced p53 
stabilization and activity after cytotoxic stress. For this purpose we used IGF-1-
stimulated MCF-7 cells treated with either Hydroxyurea or Gemcitabine. These drugs 
were chosen because they do not directly inhibit ribosome biogenesis (Derenzini et al. 
1981; Burger et al. 2010). We found that in IGF-1-stimulated MCF-7 cells both drugs 
stabilized p53 to a lesser extent than in control cells, as evaluated by Western blot 
analysis (Fig. 27A). Regarding the expression of the p53-target genes, we observed that 
the p21, BAX and PUMA mRNA level was markedly lower in IGF-1-stimulated than in 
control MCF-7 cells after either Hydroxyurea or Gemcitabine treatment (Fig. 27B). 
Therefore, these results indicated that the up-regulation of rRNA synthesis induced a 
lowering of the p53 level which was responsible for the down-regulation of the p53-
target gene response after exposure to cytotoxic stresses. 
 
                                                                                                         RESULTS 
51 
 
 
Figure 27 rRNA synthesis up-regulation reduces p53 levels and activity after drug-induced 
stress. A, Representative Western blot and densitometric analysis of p53 expression in control 
and MCF-7 cells exposed to IGF-1, treated either with 3.4 μM Hydroxyurea for 3 h or with 
Gemcitabine at the dose of 10 μg/ml for 4 h. B Real-time RT-PCR analysis of the mRNA 
expression of p21, Puma and Bax in control and MCF-7 cells exposed to IGF-1 treated either 
with 3.4 μM Hydroxyurea for 3 h or with Gemcitabine at the dose of 10 μg/ml for 4 h. 
Histograms show the values (mean ± s.d.) of three experiments.  
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DISCUSSION 
 
This study demonstrated that the control of p53 stabilization and activity in mammalian 
cells may be due to the balance between the rRNA and ribosomal proteins’ synthesis.  
p53 activation usually occur after a stress, and according the nucleolar disruption model 
in order to stabilize and activate p53 a stress must induce nucleolar disruption and 
compromise nucleolar function (Rubbi and Milner 2003). Our results demonstrated that 
these severe structural-functional changes of the nucleolus were not a necessary 
condition for p53 stabilization.  
Selective down-regulation of rRNA synthesis did not induce nucleolar disruption while 
stabilizing p53. Furthermore we showed that up-regulation of ribosomal biogenesis 
reduced the level of p53. When both the synthesis of rRNA and ribosomal proteins 
decreased, p53 was not stabilized. The meaning of p53 stabilization and activity were 
due to change of the balance between rRNA and ribosomal proteins synthesis. 
 
rRNA synthesis down-regulation increases p53 without 
disrupting nucleolar structure 
 
We demonstrated that, in consequence of a selective reduction of rRNA synthesis, p53 
is stabilized even if the nucleolar structure is not altered. In the past, studies about 
rRNA synthesis alterations were performed mainly by using the Actinomycin D that is 
able to selectively block the transcription of rRNA genes when used at low doses 
(Montanaro et al. 2007). However the rRNA synthesis inhibition induced by 
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Actinomycin D induces the release of nucleolar components in the nucleoplasm that 
gives rise to p53 stabilization (Rubbi and Milner 2003). For these reasons we looked for 
an alternative, more specific method to reduce rRNA production. In order to do this we 
reduced rRNA synthesis by silencing POLR1A. This procedure inhibited the expression 
of POLR1A mRNA and induced a specific inhibition of rRNA synthesis without any 
evidence of nucleolar disruption and no translocation of nucleolar proteins from the 
nucleolus to the nucleoplasm. When the rRNA synthesis was down-regulated by 
POLR1A silencing, p53 level was increased and this was the consequence of an 
increased amount of ribosomal proteins rpL5 and rpL11 bound to MDM2. Therefore, 
these data were consistent with a ribosomal proteins-MDM2 mediated mechanism of 
p53 stabilization after rRNA synthesis down-regulation. When both the synthesis of 
rRNA and ribosomal proteins decreased, such as after either serum deprivation or 
Rapamycin exposure, p53 was not stabilized. Serum starvation prevented p53 
accumulation also in POLR1A-silenced cells, thus indicating that p53 accumulation 
after the inhibition of rRNA synthesis by POLR1A interference was strictly dependent 
upon availability of newly synthesized ribosomal proteins. Therefore, we concluded that 
p53 stabilization after the reduction of rRNA synthesis by POLR1A interference was 
actually due to a relatively increased availability of ribosomal proteins for MDM2 
binding as a consequence of their reduced use in ribosome building. 
These results are only partially consistent with previous data suggesting that, in order to 
stabilize p53, cell stresses should induce a severe perturbation in the nucleolar structure 
with the release of the nucleolar proteins from the nucleolus, the so-called “nucleolar 
disruption” (Rubbi and Milner 2003). A lot of data support this theory and indicate that 
the mechanism involves ribosomal proteins binding with MDM2: in consequence of 
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necleolar disruption, ribosomal proteins are released from the nucleolus and leak in the 
nucleoplasm where bind MDM2 thus inhibiting p53 degradation (Zhang and Lu 2009; 
Deisenroth and Zhang 2010). Our results demonstrated that a selective and specific 
reduction of rRNA synthesis induces a p53 stabilization through the mechanism 
involving ribosomal proteins binding to MDM2 but without inducing profound 
alterations of the nucleolar morphology. The inhibition of new rRNA synthesis halt the 
progression of ribosome assembly, resulting in an excess of free ribosomal proteins. In 
turn, without adequate amount of rRNA to bind, ribosomal proteins are available to 
interact with Mdm2 and stabilize p53.  
We described a p53 stabilization model that does not require any severe stress and does 
not involve any structural alteration of the cell. This is in line with recent evidences that 
underline how p53 functions can be induced also by mild stress conditions. Indeed p53 
functions are not only involved in promoting a tumor suppressive response to acute 
stress, but p53 has a major role also in regulating diverse aspects of health and disease 
(Vousden and Lane 2009). In this way mild environmental stresses can activate the so 
called “every day functions” of p53 that work to adapt the cellular metabolism to the 
new metabolic necessities without inducing cell death or senescence. Recent studies 
have painted a more complex picture of p53 as regulator of diverse biological processes, 
modulating glucose uptake, reducing glycolysis and enhancing mitochondrial 
respiration  (Vousden and Ryan 2009). This mechanism of p53 activation may be also 
important for the modulation of those p53 functions which depend on basal levels of 
p53 or the activation of p53 by low levels of constitutive stress, such as the control of 
stem cell renewal (Meletis et al. 2006; Liu et al. 2009). 
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rRNA synthesis up-regulation reduces p53 level and activity 
 
The results obtained in cells with a reduced rRNA synthesis, prompted us to investigate 
what happened when the rRNA synthesis was up-regulated. We used three different 
experimental conditions of rRNA synthesis stimulation: cancer cells treated with insulin 
or exposed to the insulin-like growth factor 1, rat liver stimulated by cortisol and 
regenerating rat liver after partial hepatectomy. In all experimental conditions we 
observed a reduction of p53 expression level. We are aware that these conditions are not 
specifically and exclusively characterized by the stimulation of rRNA synthesis. 
However all of them lead to rRNA synthesis stimulation by different pathways and the 
consequence is always a reduced p53 level.  
The evaluation of p53 transcriptional target genes showed a reduced transcription of 
p21, BAX and PUMA, demonstrating a failure in the ability of induce a p53 response in 
all the experimental conditions characterized by an increased ribosome biogenesis. At 
this point we wondered whether the reduced p53 level in cells with increased rRNA 
synthesis might also be reflected in a reduced p53 stabilization and activity after 
cytotoxic stresses. For this purpose we used IGF-1-stimulated MCF-7 cells treated with 
either Hydroxyurea or Gemcitabine, two drugs that do not directly inhibit ribosome 
biogenesis. After drug exposure, MCF-7 cells treated with IGF-1 were able to stabilize 
p53 to a lesser extent than control cells. Also the transcription level of p21, BAX and 
PUMA was markedly lower in IGF-1-stimulated than un-stimulated MCF-7 cells after 
either Hydroxyurea or Gemcitabine treatment. These results indicated that the up-
regulation of rRNA synthesis induced a lowering of the p53 level which was 
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responsible for the down-regulation of the p53-target gene response after exposure to 
cytotoxic stresses. 
Regarding the mechanism involved in regulating p53 activation after rRNA synthesis 
up-regulation we demonstrated the key role played by ribosomal proteins-MDM2 
interaction (this mechanism of p53 stabilization is schematically represented in Fig. 28). 
In homeostatic conditions p53 level is controlled by the steady state balance between 
rRNA and ribosomal protein synthesis. Ribosomal proteins not utilized for ribosome 
building bind to MDM2, thus regulating the MDM2-mediated p53 proteasomal 
degradation. After a down-regulation of rRNA synthesis the ribosomal proteins no 
longer engaged in ribosome biogenesis bind in larger amount to MDM2, thus reducing 
the MDM2-mediated p53 proteasomal degradation with the consequent increase of p53 
stabilization. When the synthesis of rRNA is up-regulated a greater amount of 
ribosomal proteins are used for ribosome building, which are therefore no longer 
available for MDM2 binding. Thus, a greater portion of MDM2 is left free to induce 
p53 proteasomal degradation. 
Interestingly we demonstrated that, when the rRNA synthesis was up-regulated, the 
ability to activate a p53 response was impaired. These findings can have important 
implications in tumorigenesis, for example they could explain the increased risk of 
developing tumors in those non neoplastic, pathological conditions characterized by an 
up-regulated rRNA synthesis. Among these, chronic liver disease, caused by viral 
hepatitis, alcohol abuse, and inborn metabolic errors. Eighty percent of all 
hepatocellular carcinomas (HCCs) worldwide occur when chronic liver disease has 
reached the cirrhotic stage (Libbrecht et al 2005). The mechanisms underlying the 
development of chronically diseased liver in HCC are currently being investigated. 
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Interestingly, there is evidence that, as far as chronic liver diseases from viral infections 
are concerned, an increased nucleolar size of the hepatocyte is constantly associated 
with later onset of HCC. Both hepatitis B (HBV) and hepatitis C (HCV) viruses, which 
are responsible for the development of chronic liver disease, have been shown to up-
regulate the activity of the RNA polymerase I and III (Wang et al 1998). A series of 
studies performed to define whether nucleolar changes might be related to neoplastic 
transformation in chronic liver disease from viral infection demonstrated that the 
presence of abnormally enlarged hepatocyte nucleoli represent a very strong risk factor 
for developing HCC (Trerè et al 2003). In other words, only those chronic liver lesions 
in which the viral infection induced hypertrophy, and consequently a functional up-
regulation of nucleoli, would be susceptible to cancer development (Montanaro et al 
2008). Thus, it is likely that the up-regulation of rRNA synthesis could be responsible 
of the increased cancer susceptibility by impairing p53 function according the 
mechanism described above. 
Furthermore the reported mechanism of p53 regulation consequent to rRNA synthesis 
up-regulation might explain the increased risk of cancer onset in people with obesity, 
insulin-resistance and type II diabetes which are characterized by a hyperinsulinemic 
status with activation of the insulin and IGF-1 pathways (Renehan et al. 2006, 2008; 
Frasca et al. 2008; Cannata et al. 2010). This mechanism might be also responsible for 
the worse evolution of cancer in patients with the above-mentioned metabolic features, 
by reducing the efficacy of the anti-tumour therapies that activate p53 (Renehan et al. 
2006, 2008; Frasca et al. 2008; Cannata et al. 2010).    
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Figure 28 Schematic representation of how the balance between rRNA and ribosomal 
protein synthesis regulates p53 levels. A Homeostatic rRNA and ribosomal protein 
synthesis. The p53 level is controlled by the steady-state balance between rRNA and ribosomal 
protein synthesis. Ribosomal proteins not utilized for ribosome building bind to MDM2, thus 
regulating the MDM2-mediated p53 proteasomal degradation. B rRNA synthesis down-
regulation. After a down-regulation of rRNA synthesis the ribosomal proteins no longer 
engaged in ribosome biogenesis bind in larger amount to MDM2, thus reducing the MDM2-
mediated p53 proteasomal degradation with the consequent increase of p53 stabilization. C 
rRNA synthesis up-regulation. After an up-regulation of rRNA synthesis a greater amount of 
ribosomal proteins are used for ribosome building, which are therefore no longer available for 
MDM2 binding. Thus, a greater portion of MDM2 is left free to induce p53 proteasomal 
degradation. 
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